Immunotherapy for CALR-mutated Myeloproliferative Neoplasms
Category: Pharmaceutical
Exhibitor: NATIONAL YANG MING CHIAO TUNG UNIVERSITY
Booth No: N726
Characteristic
Led by clinical hematologist-oncologist, we developed an Fc-optimized antibody targeting CALR-mutant myeloproliferative neoplasms. Utilizing AlphaFold 3 AI for precise epitope mapping, our lead asset demonstrates sub-nanomolar affinity. Unlike current symptomatic treatments and competitors’ neutralization therapies, our antibody actively eliminates pathogenic clones. Currently entering IND-enabling studies, this technology holds immense potential for global licensing and clinical translation.
Other Products
Products you may be interested in
Highest Rated Products